Updated Guidance On Expedited Review Removes 2002 MDUFMA Conditions
This article was originally published in The Gray Sheet
Executive Summary
FDA will no longer require device firms to satisfy extra conditions in order for their expedited PMA applications to fall under FDA review performance goals, according to guidance released Feb. 29
You may also be interested in...
FDA Guidance Aims To Hit MDUFMA Expedited Review Performance Goals
Expedited review status requires manufacturers to make all related scientific and regulatory issues a top priority, according to an FDA guidance document
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.